The Effect of 4mg Saroglitazar on Patients of Diabetes Dyslipidemia with Nonalcoholic Fatty Liver Disease for 24 Weeks at Diabetes Care Centre

Trial Profile

The Effect of 4mg Saroglitazar on Patients of Diabetes Dyslipidemia with Nonalcoholic Fatty Liver Disease for 24 Weeks at Diabetes Care Centre

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Saroglitazar (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2015 New trial record
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top